Get the Stockscreener App
1.95
13.37%
0.23
Estrella Immunopharma Inc stock is traded at $1.95, with a volume of 178.46K.
It is up +13.37% in the last 24 hours and down -14.85% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
See More
Previous Close:
$1.72
Open:
$1.67
24h Volume:
178.46K
Relative Volume:
0.67
Market Cap:
$73.64M
Revenue:
-
Net Income/Loss:
$-8.82M
P/E Ratio:
-6.50
EPS:
-0.3
Net Cash Flow:
$-18.01M
1W Performance:
+3.72%
1M Performance:
-14.85%
6M Performance:
+96.97%
1Y Performance:
+62.50%
1-Day Range:
$1.63
$2.05
1-Week Range:
$1.52
$2.27
52-Week Range:
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.95 | 64.96M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com South Africa
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World
How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-19 23:49:15 - newser.com
Is Estrella Immunopharma Inc. stock oversold or undervaluedStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
What data driven models say about Estrella Immunopharma Inc.’s futureJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Is now a turning point for Estrella Immunopharma Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Is Estrella Immunopharma Inc. building a consolidation baseMarket Trend Review & Precise Buy Zone Tips - newser.com
Will Estrella Immunopharma Inc. stock gain from government policies2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-11-15 19:23:21 - newser.com
Is Estrella Immunopharma Inc. reversing from oversold territoryEntry Point & Step-by-Step Swing Trade Plans - newser.com
How to integrate Estrella Immunopharma Inc. into portfolio analysis tools - newser.com
Published on: 2025-11-14 10:46:07 - newser.com
10-Q: Quarterly report - 富途牛牛
Get in on Estrella Immunopharma Inc’s (ESLA) buy-in window today! - Setenews
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):